EP
CNST

Eudaimonia Partners’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Eudaimonia Partners’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-277
Closed -$6K – 1519
2021
Q1 		$6K Buy
+277
New +$8.39K ﹤0.01% 1304

Other funds holding CNST

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eudaimonia Partners's CNST Position: Q2 2021 in Review

Eudaimonia Partners sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q2 2021, closing a stake of 277 shares — an estimated $6K sold.

Eudaimonia Partners first reported a position in CNST in Q1 2021 and held it in 1 quarter. The position peaked at $6K in Q1 2021. 153 funds tracked by Wall St. Rank hold CNST as of Q2 2021.

  • Eudaimonia Partners reported no remaining Constellation Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Eudaimonia Partners sold 277 Constellation Pharmaceuticals, Inc. shares in Q2 2021, an estimated $6K.
  • Eudaimonia Partners first reported a position in Constellation Pharmaceuticals, Inc. in Q1 2021 and held it in 1 quarter.
  • Eudaimonia Partners's Constellation Pharmaceuticals, Inc. position peaked at $6K in Q1 2021.
  • 153 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.